Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 4/20 | 0.68 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.68 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.68 |
| ▸ | SRM | P19623 | 1/20 | 0.68 |
| ▸ | SMS | P52788 | 1/20 | 0.68 |
| ▸ | DPP4 | P27487 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.67 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.67 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.67 |
| ▸ | GAPDH | P04406 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.67 |
| ▸ | STAT6 | P42226 | 1/20 | 0.67 |
| ▸ | PI4KA | P42356 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184440 | 1.00 | DOT1L (0.68) | DOT1LDNMT3BPRMT7SRMSMS | |
| SCHEMBL30760710 | 0.98 | SRM (0.71) | DOT1LDNMT3BPRMT7SRMSMS | |
| SCHEMBL5007882 | 0.95 | SRM (0.67) | DOT1LDNMT3BPRMT7SRMSMS | |
| SCHEMBL28374784 | 0.91 | EHMT1 (0.74) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL13667507 | 0.91 | EHMT1 (0.74) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL13986406 | 0.89 | ADORA3 (0.73) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL7062240 | 0.89 | ADORA3 (0.73) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL7062257 | 0.89 | ADORA3 (0.73) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL17568775 | 0.88 | EHMT1 (0.70) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL15984531 | 0.88 | EHMT1 (0.70) | DOT1LDPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023249908-A1 | USE OF NON-TOXIC POLYAMINE ANALOGUES AND/OR INHIBITORS OF POLYAMINE BIOSYNTHESIS TO RE-BALANCE NATURAL POLYAMINE LEVELS IN SNYDER-ROBINSON SYNDROME AND RELATED DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-12-28 | — | — | WO | claimed |
| EP-1357881-A4 | INHIBITORS OF SPERMIDINE SYNTHASE FOR THE TREATMENT OF OSTEOARTHRITIS AND CARTILAGE REHABILITATION | QUARK PHARMACEUTICALS INC (US) | 2009-02-18 | — | — | EP | claimed |
| US-20040229886-A1 | Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation | QUARK BIOTECH, INC. & SHIONOGI CO., LTD. | 2004-11-18 | — | — | US | claimed |
| US-6696454-B2 | ADMINISTERING AN INHIBITOR OF SPERMIDINE BIOSYNTHESIS; PREFERRED ARE DCHA (DICYCLOHEXYLAMINE), ADODATO, AND TRANS-4-METHYLCYCLOHEXYLAMINE (4MCHA) | QUARK BIOTECH, INC. | 2004-02-24 | — | — | US | claimed |
| EP-1357881-A2 | INHIBITORS OF SPERMIDINE SYNTHASE FOR THE TREATMENT OF OSTEOARTHRITIS AND CARTILAGE REHABILITATION | Quark Biotech, Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| US-20020160978-A1 | Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation | QUARK PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | claimed |
| WO-2002058623-A2 | INHIBITORS OF SPERMIDINE SYNTHASE FOR THE TREATMENT OF OSTEOARTHRITIS AND CARTILAGE REHABILITATION | QUARK BIOTECH, INC. (US) | 2002-08-01 | — | — | WO | claimed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050176828-A1 | Hydrophobic polyamine analogs and methods for their use | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| US-6696454-B2 | ADMINISTERING AN INHIBITOR OF SPERMIDINE BIOSYNTHESIS; PREFERRED ARE DCHA (DICYCLOHEXYLAMINE), ADODATO, AND TRANS-4-METHYLCYCLOHEXYLAMINE (4MCHA) | QUARK BIOTECH, INC. | 2004-02-24 | — | — | US | disclosed |
| EP-1357881-A2 | INHIBITORS OF SPERMIDINE SYNTHASE FOR THE TREATMENT OF OSTEOARTHRITIS AND CARTILAGE REHABILITATION | Quark Biotech, Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | AMINEX THERAPEUTICS, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20020160978-A1 | Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation | QUARK PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | disclosed |
| WO-2002058623-A2 | INHIBITORS OF SPERMIDINE SYNTHASE FOR THE TREATMENT OF OSTEOARTHRITIS AND CARTILAGE REHABILITATION | QUARK BIOTECH, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | DOT1L 595/4885DNMT3B 1116/4885PRMT7 31/4885 |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | SRM, PMP22, SMS | DOT1L 2184/4885DNMT3B 563/4885PRMT7 182/4885 |
| US-20050176828-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | DOT1L 595/4885DNMT3B 1116/4885PRMT7 31/4885 |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | SLC7A1, SRM, SLC16A1 | DOT1L 862/4885DNMT3B 2424/4885PRMT7 279/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | DOT1L 4058/4885DNMT3B 118/4885PRMT7 642/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | DOT1L 4058/4885DNMT3B 118/4885PRMT7 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.